Gilead Drug Up for European Review - Analyst Blog - NASDAQ

The MAA was filed on the basis of pharmacokinetic data from a study which revealed that the addition of cobicistat boosted the exposure of HIV therapies Reyataz and Prezista similar to Abbott Laboratories ' ( ABT) HIV therapy Norvir. Currently ...

Gilead Quad Tablet Gets FDA Committee Approval Nod - AIDSmeds.com HIV/AIDS Treatment News

For this—and as a potential alternative to low-dose Norvir for use in combination with other medications—Gilead has developed cobicistat, a potent pharmacokinetic enhancer without any activity against HIV. The approval recommendation was ...

Vivus Announces FDA Approval Of STENDRA™ (avanafil) Tablets For The Treatment Of Erectile Dysfunction - Yahoo Finance

STENDRA may affect the way other medicines work.  Tell your healthcare provider if you take any of the following; medicines called HIV protease inhibitors, such as ritonavir (Norvir), indinavir (Crixivan), saquinavir (Fortavase or Invirase ...

The Zacks Analyst Blog Highlights: Gilead Sciences, Abbott Labs, Alliance Data Systems Corporation, Blue Nile and Bristol-Myers Squibb - CNBC

While Norvir is marketed by Abbott Labs (NYSE:ABT), Reyataz is marketed by Bristol-Myers Squibb (NYSE:BMY). While reviewing the application, the panel voted overwhelmingly (13-1) in favor of clearing the combination pill (a single tablet regimen ...

AIDS Advocates to Protest Gilead over Drug Pricing at May 10th Shareholders' Meeting - Marketwatch

The "Quad" combines Truvada with Elvitegravir (an integrase inhibitor similar to Merck's Isentress) and Cobicistat (a blood booster similar to the decade-old Norvir). The FDA is currently reviewing Gilead's application to approve the Quad ...

HIV Drug Maker Gilead Sciences Scores Two Wins - Minyanville

The unapproved medicines are elvitegravir, which is among a new class of drugs known as integrase inhibitors and cobicistat, a booster drug similar to Abbott Laboratories’ (ABT) Norvir. Quad would be used as a first-line treatment for HIV patients.